Additional data from the MINDACT trial showed that not all young women with breast cancer are at high risk of disease recurrence. MammaPrint classified 48% of the 1,100 patients as genomic High Risk, compared to 61% using clinical risk assessment alone. The outcome for women with a MammaPrint Low Risk result within the three age categories of up to 45, 45-55 and 55 or over, was a five-year Distant Metastasis-Free Survival (DMFS) of 95-98%. These clinically-relevant results add important additional data to limited available evidence on genomic expression in young early-stage breast cancer patients.
Dr. William Audeh, Chief Medical Officer at Agendia, said:
Ad Statistics
Times Displayed: 50213
Times Visited: 1424 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
“These impressive data represent the highlights of eleven posters and discussions showcasing new MammaPrint and BluePrint data presented during SABCS this year, truly demonstrating the versatility and value of these tests. We are seeing the utility of using MammaPrint to pre-select patients for the I-SPY 2 trial in the shape of the impressive first long-term survival outcomes, plus encouraging cost-effectiveness data to support the level 1A evidence already proving the clinical benefits of the test.
“The continuing value of the unique, and independent MINDACT trial has also been demonstrated in additional data that will enable physicians to better support younger patients with breast cancer and tailor treatment based on genomic risk-of-recurrence, a group for whom further evidence was certainly needed.”
1 Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Oral presentation at SABCS. December 2017; San Antonio, Texas.
2 MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer. Poster presented at SABCS. December 2017; San Antonio, Texas.
3 Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC10041/BIG 03-04 MINDACT trial. Poster presented at SABCS. December 2017; San Antonio, Texas.
Back to HCB News
